Home Stimulation for Brain-Asphyxiated Infants
|Hypoxia, Brain Hypoxia-Ischemia, Brain||Behavioral: Infant stimulation||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Neuroplasticity of Brain-Asphyxiated Infants: Efficacy of Intervention|
|Study Start Date:||September 1999|
|Primary Completion Date:||August 2004 (Final data collection date for primary outcome measure)|
Although the incidence of brain injury in infants is only 2 to 5 per 1000 births, the legal and medical costs, the developmental delays, and the impact on the family are profound. Twenty to 30% of survivors of brain injury have some long-term neurologic sequelae.
This randomized controlled trial will enroll 120 term and near-term neonates with a history of asphyxia to 1-year of a standard follow-up program (provided by the Los Angeles Regional Centers) or a home-based intervention program (Utah State University's Developmental Curriculum and Monitoring System, CAMS). The experimental intervention will include individualized cognitive/neuromotor stimulation given by the child's parents under the guidance of public health nurses. Following the intervention, measures will be used to determine functional capacity (Bayley II scale and neurologic examination), behavioral outcomes (HOME and NCAST by developmental specialists), and maternal outcomes (including parent-infant interaction and perceived stress). Infants will be assessed after the 1-year intervention by psychologists and physicians masked to the intervention. Functional MRI brain studies will be conducted at discharge and 18 months of age at UCLA to assess qualitative and quantitative sensorimotor representation. Secondary outcomes include care stress and social support as reported by parents, and demographics and medical factors obtained from the hospital records.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006516
|United States, California|
|University of California at Los Angeles|
|Los Angeles, California, United States, 90095|
|Principal Investigator:||Meena Garg, MD||University of California at Los Angeles|